178 related articles for article (PubMed ID: 35305596)
21. Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer.
Santarpia M; Menis J; Chaib I; Gonzalez Cao M; Rosell R
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):831-840. PubMed ID: 31356117
[No Abstract] [Full Text] [Related]
22. Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers.
Yu HA; Ahn MJ; Cho BC; Gerber DE; Natale RB; Socinski MA; Giri N; Quinn S; Sbar E; Zhang H; Giaccone G
Lung Cancer; 2017 Oct; 112():195-199. PubMed ID: 29191595
[TBL] [Abstract][Full Text] [Related]
23. Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02).
Tanaka H; Sakamoto H; Akita T; Ohyanagi F; Kawashima Y; Tambo Y; Tanimoto A; Horiike A; Miyauchi E; Tsuchiya-Kawano Y; Yanagitani N; Nishio M
Thorac Cancer; 2022 May; 13(10):1471-1478. PubMed ID: 35415873
[TBL] [Abstract][Full Text] [Related]
24. Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
Ai X; Song Z; Jian H; Zhou Z; Chen Z; Yu Y; Li Z; Lu S
BMC Cancer; 2021 Sep; 21(1):1033. PubMed ID: 34530760
[TBL] [Abstract][Full Text] [Related]
25. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.
Ramalingam SS; Jänne PA; Mok T; O'Byrne K; Boyer MJ; Von Pawel J; Pluzanski A; Shtivelband M; Docampo LI; Bennouna J; Zhang H; Liang JQ; Doherty JP; Taylor I; Mather CB; Goldberg Z; O'Connell J; Paz-Ares L
Lancet Oncol; 2014 Nov; 15(12):1369-78. PubMed ID: 25439691
[TBL] [Abstract][Full Text] [Related]
26. The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study.
Cheng WC; Lin CC; Liao WC; Lin YC; Chen CH; Chen HJ; Tu CY; Hsia TC
BMC Cancer; 2024 Feb; 24(1):228. PubMed ID: 38373960
[TBL] [Abstract][Full Text] [Related]
27. A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report.
Zhou T; Xiong Q; Hong C; Wang Q; Wang W; Xu C; Cai J;
Medicine (Baltimore); 2022 Aug; 101(34):e30269. PubMed ID: 36042660
[TBL] [Abstract][Full Text] [Related]
28. Dacomitinib as a retreatment for advanced non-small cell lung cancer patient with an uncommon EGFR mutation.
Morita A; Hosokawa S; Yamada K; Umeno T; Kano H; Kayatani H; Shiojiri M; Sakugawa M; Bessho A
Thorac Cancer; 2021 Apr; 12(8):1248-1251. PubMed ID: 33651475
[TBL] [Abstract][Full Text] [Related]
29. Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040).
Fukui T; Sasaki J; Igawa S; Kada A; Saito TI; Kogure Y; Okamoto H; Naoki K
BMC Cancer; 2022 Dec; 22(1):1314. PubMed ID: 36522630
[TBL] [Abstract][Full Text] [Related]
30. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
31. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
[TBL] [Abstract][Full Text] [Related]
32. Prophylactic treatment of dacomitinib-induced skin toxicities in epidermal growth factor receptor-mutated non-small-cell lung cancer: A multicenter, Phase II trial.
Iwasaku M; Uchino J; Chibana K; Tanzawa S; Yamada T; Tobino K; Uchida Y; Kijima T; Nakatomi K; Izumi M; Tamiya N; Kimura H; Fujita M; Honda R; Takumi C; Yamada T; Kaneko Y; Kiyomi F; Takayama K
Cancer Med; 2023 Jul; 12(14):15117-15127. PubMed ID: 37269194
[TBL] [Abstract][Full Text] [Related]
33. The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050.
Paty J; Sandin R; Reisman A; Wu YL; Migliorino MR; Zhou X; Cheng Y; Lee KH; Nakagawa K; Niho S; Corral J; Płużański A; Linke R; Meyers O; Mok TS
Future Oncol; 2021 Mar; 17(7):783-794. PubMed ID: 33164569
[No Abstract] [Full Text] [Related]
34. Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial.
Park K; Cho BC; Kim DW; Ahn MJ; Lee SY; Gernhardt D; Taylor I; Campbell AK; Zhang H; Giri N; Letrent SP; O'Connell J; Heo DS
J Thorac Oncol; 2014 Oct; 9(10):1523-31. PubMed ID: 25521398
[TBL] [Abstract][Full Text] [Related]
35. Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment.
Kuiper JL; Heideman DA; Würdinger T; Grünberg K; Groen HJ; Smit EF
Clin Lung Cancer; 2015 Jan; 16(1):60-6. PubMed ID: 25242669
[TBL] [Abstract][Full Text] [Related]
36. Dacomitinib in non-small-cell lung cancer: a comprehensive review for clinical application.
Sun H; Wu YL
Future Oncol; 2019 Aug; 15(23):2769-2777. PubMed ID: 31401844
[TBL] [Abstract][Full Text] [Related]
37. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
38. Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study.
Jung HA; Park S; Lee SH; Ahn JS; Ahn MJ; Sun JM
ESMO Open; 2023 Dec; 8(6):102068. PubMed ID: 38016250
[TBL] [Abstract][Full Text] [Related]
39. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
Sugawara S; Oizumi S; Minato K; Harada T; Inoue A; Fujita Y; Maemondo M; Yoshizawa H; Ito K; Gemma A; Nishitsuji M; Harada M; Isobe H; Kinoshita I; Morita S; Kobayashi K; Hagiwara K; Kurihara M; Nukiwa T
Ann Oncol; 2015 May; 26(5):888-894. PubMed ID: 25669832
[TBL] [Abstract][Full Text] [Related]
40. Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
Zheng L; Wang Y; Xu Z; Yang Q; Zhu G; Liao XY; Chen X; Zhu B; Duan Y; Sun J
Oncologist; 2019 Aug; 24(8):1031-e612. PubMed ID: 31040256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
